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Reply to Ozaras et al
To the Editor—We appreciate the 
concern raised by Ozaras et al regard-
ing the hepatitis B surface antibody 
(anti-HBs) status of the 103 hepati-
tis C virus (HCV)–infected patients 
who were hepatitis B surface antigen 
(HBsAg) negative and hepatitis B core 
antibody (anti-HBc) positive and had 
no evidence of hepatitis B virus (HBV) 
reactivation during or following treat-
ment with ledipasvir/sofosbuvir [1, 2]. 
To address this concern, we retrospec-
tively determined the anti-HBs status 
of the 103 patients who were positive 
for anti-HBc, by analyzing archived 
samples using the ADVIA Centaur 
Anti-HBs Reagent Kit (Seimens 
Healthcare Diagnostics, Tarrytown, 
New York). Of 103 patient samples 
analyzed, 37 (36%) were anti-HBs neg-
ative, 63 (61%) were anti-HBs positive, 
and 3 (3%) could not be evaluated be-
cause the remaining samples were in-
adequate. Of the 2 patients identified 
in our initial analysis as being HBsAg 
negative and anti-HBc positive with 
detectable HBV DNA below the low-
er limit of quantification, both were 
found to be negative for anti-HBs. 
Importantly, none of the 37 anti-HBc–
positive/HBs-negative patients experi-
enced HBV reactivation in our study, 
including the 2 patients with detecta-
ble HBV DNA.
Published case reports suggest that 
clinical HBV reactivation is a rare 
occurrence. The majority of described 
cases occurred in persons who were 
HBsAg positive, indicative of active 
HBV infection. Some of these patients 
may have met criteria for HBV treat-
ment prior to the initiation of HCV 
therapy. In the case series reported by 
Bersoff-Matcha and colleagues from 
the US Food and Drug Administration, 
the status of HBV infection was incom-
plete for many patients, which lim-
its the interpretation of the risk of 
HBV flare, particularly among those 
reported to be HBsAg negative [3]. Liu 
and colleagues presented data in 2016 
on HBV reactivation in 134 patients 
receiving DAA treatment for HCV [4]. 
Of the 134 patients, 81 patients were 
HBsAg negative and anti-HBc positive. 
No evidence of HBV reactivation was 
observed in these 81 patients, which is 
consistent with our findings. The pre-
cise risk of HBV reactivation is diffi-
cult to estimate, but the relatively high 
global prevalence of HBV infection in 
persons with chronic HCV infection 
and the small number of cases of HBV 
reactivation or alanine aminotrans-
ferase flare reported among the >1 mil-
lion persons treated with direct-acting 
antivirals (DAAs) for HCV suggest that 
the risk is low [5].
We believe that HCV-infected patients 
should be screened for HBV infection 
prior to initiation of DAAs and, for those 
found to have active HBV infection, HBV 
treatment guidelines should be followed. 
Given the benefits of successful HCV 
treatment, the risk of HBV reactivation 
should not be overstated.
Notes
Financial support. This work was supported 
by Gilead Sciences.
Potential conflicts of interest. M.  S. S.  has 
received research grants from AbbVie, Bristol-
Myers Squibb, Gilead, Janssen, and Merck, and 
personal fees from AbbVie, Gilead, Janssen, 
Cocrystal, Merck, and Trek. D. M. B. and J. C. 
Y.  are employees of and hold stock interest in 
Gilead. E.  J. G.  has received research grants 
from Gilead Sciences; has served on adviso-
ry boards for AbbVie, Boehringer Ingelheim, 
Gilead Sciences, Janssen, Novartis, Roche, and 
Tibotec; and has served on the speaker’s bu-
reaus for Gilead Sciences, Novartis, Roche, and 
Tibotec. All authors have submitted the ICMJE 
Form for Disclosure of Potential Conflicts of 
Interest. Conflicts that the editors consider rele-
vant to the content of the manuscript have been 
disclosed.
Mark S. Sulkowski,1 Diana M. Brainard,2 
Jenny C. Yang,2 and Edward J. Gane3
1Johns Hopkins University School of Medicine, Baltimore, 
Maryland; 2Gilead Sciences, Foster City, California; and 3New 
Zealand Liver Transplant Unit, Auckland City Hospital
References
1. Ozaras R, Balkan II, Yemisen M, et al. Reactivation 
of hepatitis B virus following treatment of hepatitis 
C virus infection in coinfected patients. Clin Infect 
Dis 2017; 64:1461–2.
2. Sulkowski MS, Chuang WL, Kao JH, et al. No evi-
dence of reactivation of hepatitis B virus among 
patients treated with ledipasvir-sofosbuvir for 
hepatitis C virus infection. Clin Infect Dis 2016; 
63:1202–4.
3. Bersoff-Matcha S, Cao K, Jason M, et al. Hepatitis 
B reactivation associated with direct acting anti-
viral therapy for hepatitis C: a review of sponta-
neous post-marketing cases. Presented at the 67th 
Annual Meeting of the American Association for 
the Study of Liver Diseases: The Liver Meeting 
2016, Boston, MA, 11–15 November 2016. 
[Abstract LB-17].
4. Liu C-H, Liu C-J, Su T-H, et al. Hepatitis B virus 
reactivations in patients receiving interferon-free 
direct acting antiviral agents for chronic hepatitis 
C virus infection. Presented at the 67th Annual 
Meeting of the American Association for the 
Study of Liver Diseases: The Liver Meeting 2016, 
Boston, MA, 11–15 November 2016 [Abstract 
831].
5. World Health Organization. Over 1 million 
treated with highly effective hepatitis C medicines. 
Available at: http://www.who.int/mediacentre/
news/releases/2016/hepatitis-c-medicines/en/. 
Accessed 15 February 2017.
C O R R E S P O N D E N C E
 
© The Author 2017. Published by Oxford University Press for 
the Infectious Diseases Society of America. All rights reserved. 
For permissions, e-mail: journals.permissions@oup.com.
DOI: 10.1093/cid/cix213
Correspondence: M. S. Sulkowski, Johns Hopkins University 
School of Medicine, 1800 Orleans Street, 1803 Building, Room 
445, Baltimore, Maryland 21287 (msulkowski@jhmi.edu).
C O R R E S P O N D E N C E
Time Efficiency Assessment 
of Antimicrobial Stewardship 
Strategies
To the Editor—We read with interest 
the recent article in Clinical Infectious 
Diseases by Tamma et al [1], which fo-
cused on the efficacy of different antimi-
crobial stewardship methods, demon-
strating that post-prescription review with 
feedback (PPRF) was more effective at 
reducing antimicrobial consumption over 
time than pre-prescription authorization. 
The study was performed on medical in-
patients, but hospitals contain many oth-
er cohorts, such as surgical inpatients, in 
whom antimicrobial use is also high and 
often inappropriate [2]. PPRF can take 
many forms but is invariably both human 
resource and time intensive. Many hospi-
tals may lack the resources to initiate this 
level of stewardship universally [3, 4], and 
there is therefore a need to identify the 
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form of PPRF that most efficiently impacts 
inappropriate antimicrobial prescribing 
[5, 6].
We performed a prospective, obser-
vational study that compared different 
forms of PPRF: ward round reviews 
on acute medical wards, ward round 
reviews on surgical recovery wards, and 
telephone reviews with clinical teams 
caring for patients receiving carbapen-
ems, cephalosporines, or quinolones. 
Each stewardship review episode was 
performed by 2 microbiologists and a 
pharmacist, who collected no more data 
than needed for routine practice and 
were not aware that the data would be 
used comparatively in the study. The 3 
stewardship modalities occurred daily 
for 45, 90, or 60 minutes—for medical 
rounds, surgical rounds, and telephone 
reviews, respectively—and there was 
no overlap in the patients reviewed. All 
antimicrobial prescriptions reviewed 
were quantified and any intervention was 
recorded, with an intervention defined as 
a change to antimicrobial prescription, 
including starting or stopping treatment 
with a medication or modifying the 
duration of treatment or mode of admin-
istration. For the purpose of comparison, 
we considered telephone stewardship to 
be the control group. We calculated both 
the proportion of reviews resulting in an 
intervention and the rate of interven-
tion per hour of stewardship across the 3 
stewardship modalities.
A total of 1928 antimicrobial prescrip-
tions were reviewed. Both surgical (37.24%) 
and medical (9.35%) stewardship ward 
rounds resulted in a significantly higher 
proportion of interventions than telephone 
reviews (4.34%) (Table 1). However, after 
controlling for time, the rate of interven-
tions per hour was higher for medical stew-
ardship rounds (2.26 interventions / hour) 
than for both surgical (1.70 interventions / 
hour) and telephone (0.48 interventions / 
hour) rounds (Table 1).
In conclusion, our study supports the 
observations made by Tamma et  al [1] 
that hospital ward–based PPRF, though 
resource intensive, is an effective form 
of antimicrobial stewardship. We extend 
their findings by raising the importance 
of time efficiency, demonstrating that 
although surgical patient stewardship 
rounds result in a high absolute number 
and proportion of interventions, they are 
labor intensive, and medical ward rounds 
resulted in a similar number of interven-
tions per hour of stewardship time. Both 
approaches were significantly better than 
telephone stewardship in terms of both the 
proportion and rate of stewardship inter-
ventions. We propose that other hospitals 
looking to assess and prioritize the impact 
of their stewardship programs should also 
incorporate a standardized time-based 
measure of stewardship efficiency.
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Table 1. Number, Proportion and Rate of Interventions by Stewardship Modality
Stewardship Approach
Prescriptions Reviewed, 
No.
Stewardship Interventions
Intervention Rate, Interventions 
per Hour of Stewardship (95% CI)
Hazard Ratio  
(95% CI)No. (10) Odds Ratio (95% CI)
Telephone 691 30 (4.34) … 0.48 (.34–.69) …
Medical round 802 75 (9.35) 2.27 (1.46–3.52) 2.26 (1.8–2.83) 4.69 (3.07–7.17)
Surgical round 435 162 (37.24) 13.07 (8.64–19.79) 1.70 (1.36–1.98) 3.53 (2.39–5.21)
Abbreviation: CI, confidence interval.
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C O R R E S P O N D E N C E
Optimizing Proton Pump 
Inhibitor Use to Reduce 
Antimicrobial Resistance Rates?
To the Editor—With the greatest 
interest we read the study of Huizinga 
and colleagues on the impact of proton 
pump inhibitor (PPI) use on colonization 
with extended-spectrum β-lactamase– 
producing Enterobacteriaceae [1]. In 
our multicenter Antibiotic Therapy 
Optimization Study (ATHOS), the 
study group obtained rectal swabs of 
4376 patients on hospital admission 
and determined the prevalence for 
